Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

If validated prospectively, the findings could be ‘transformative’ for patients with no current medical options.

With studies showing potential for SGLT2 inhibitors in heart failure ... to consider its product’s role for heart failure patients who do not have diabetes. Heart failure is estimated to ...

The deaths are also partly the result of medical successes: People are living longer, and more people are surviving heart ...

SGLT-2 inhibitors canagliflozin, empagliflozin, and dapagliflozin showed overall comparable effectiveness on cardiovascular outcomes in T2D.

A new study, authored by KBH Professor Jan Inge Henter and published in the New England Journal of Medicine, has investigated ...

A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...

"The benefits seen here are distinct from those seen with the other very popular SGLT2 inhibitors in widespread clinical use for diabetes, heart failure, and kidney disease." "Few people had ...

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...

Preoperative use of SGLT2 inhibitors among patients with type 2 diabetes undergoing emergency surgery was not associated with ...

For example, someone with a new diagnosis of heart failure may start on a low dose of ARNI and beta-blocker, and within a few days or weeks, add a mineralocorticoid antagonist and SGLT2 inhibitor ...

“These findings reinforce the use of dapagliflozin 10 mg, or other SGLT2 inhibitors, when the therapeutic goal is to reduce the risk of heart failure,” write HoJin ... which observational studies do ...